FDA Clears New Targeted Therapy for Specific Metastatic Prostate Cancer

The FDA has granted approval for Truqap, in combination with abiraterone and prednisone, to treat adults with PTEN-deficient metastatic prostate cancer. This marks a significant development as it's the first targeted treatment specifically approved for patients with this genetic profile in androgen-sensitive metastatic prostate cancer. The decision is based on positive outcomes from the Phase 3 CAPItello-281 trial, enabling earlier biomarker-guided therapy.